Taisho Pharma Co
Taisho Pharmaceutical Co., Ltd., commonly referred to as Taisho Pharma, is a prominent player in the pharmaceutical industry, headquartered in Japan. Established in 1912, the company has a rich history of innovation and growth, with significant operations across Asia and beyond. Taisho Pharma focuses on a diverse range of sectors, including over-the-counter (OTC) medications, prescription drugs, and health supplements. Its core products, such as pain relief and digestive aids, are distinguished by their commitment to quality and efficacy. With a strong market position, Taisho Pharma has achieved notable milestones, including strategic partnerships and expansions that enhance its global footprint. The company continues to be recognised for its contributions to healthcare, making it a trusted name in the pharmaceutical landscape.
DitchCarbon Score
How does Taisho Pharma Co's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Taisho Pharma Co's score of 20 is higher than 64% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Taisho Pharma Co's reported carbon emissions
In 2021, Taisho Pharma Co, headquartered in Japan, reported total carbon emissions of approximately 50,085,000 kg CO2e. This figure includes 22,353,000 kg CO2e from Scope 1 emissions and 27,732,000 kg CO2e from Scope 2 emissions. Additionally, the company disclosed Scope 3 emissions, which totalled approximately 47,764,000 kg CO2e from capital goods, alongside other categories such as purchased goods and services, employee commute, and waste generated in operations. Over the years, Taisho Pharma has shown a trend of fluctuating emissions, with a peak in 2017 at about 61,603,000 kg CO2e. However, by 2021, the company managed to reduce its total emissions from 51,887,000 kg CO2e in 2020, indicating a commitment to lowering its carbon footprint. Despite these reductions, Taisho Pharma has not set specific reduction targets or initiatives under the Science Based Targets initiative (SBTi) or other formal climate pledges. The absence of defined reduction goals suggests that while the company is actively monitoring its emissions, it may need to enhance its climate commitments to align with industry standards and global climate goals.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2013 | 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|---|
| Scope 1 | 26,236,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 30,028,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | - | 000,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Taisho Pharma Co is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
